Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CYTK OTCMKTS:EVTCY NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.99-0.9%$23.42$13.40▼$26.65$4.38B0.752.03 million shs1.32 million shsCYTKCytokinetics$35.33-5.4%$36.25$29.31▼$59.39$4.23B0.621.72 million shs3.22 million shsEVTCYEvotec$3.50-0.3%$3.95$14.22▼$26.57$1.16B0.982,407 shs23,954 shsTGTXTG Therapeutics$29.33+1.3%$33.28$21.11▼$46.48$4.65B1.882.91 million shs1.82 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+0.97%+10.45%+21.05%+56.76%CYTKCytokinetics0.00%-7.85%-3.71%+13.20%-38.10%EVTCYEvotec0.00%-3.85%-12.06%-11.84%-7.16%TGTXTG Therapeutics0.00%-0.37%-16.25%-17.96%+24.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.7764 of 5 stars3.32.00.00.02.54.22.5CYTKCytokinetics3.6432 of 5 stars3.51.00.04.63.50.80.0EVTCYEvotecN/AN/AN/AN/AN/AN/AN/AN/ATGTXTG Therapeutics4.6498 of 5 stars3.41.00.03.53.62.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.61Moderate Buy$28.8811.10% UpsideCYTKCytokinetics 2.93Moderate Buy$71.58102.61% UpsideEVTCYEvotec 0.00N/AN/AN/ATGTXTG Therapeutics 2.75Moderate Buy$46.2557.69% UpsideCurrent Analyst Ratings BreakdownLatest EVTCY, TGTX, CYTK, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025ACADACADIA PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.008/8/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $77.008/7/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025ACADACADIA PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$15.00 ➝ $17.008/7/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.008/7/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$23.00 ➝ $24.008/7/2025ACADACADIA PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$37.00 ➝ $38.007/30/2025CYTKCytokineticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform7/24/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $34.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.006/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.58$0.70 per share36.87$4.40 per share5.91CYTKCytokinetics$85.74M49.31N/AN/A($1.15) per share-30.72EVTCYEvotec$572.16M2.02$0.03 per share105.53$2.52 per share1.39TGTXTG Therapeutics$329M14.15$0.12 per share244.49$1.43 per share20.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3319.5434.206.6221.80%14.69%9.41%11/5/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)EVTCYEvotec$7.14M$0.418.54∞N/A20.85%16.02%7.81%N/ATGTXTG Therapeutics$23.38M$0.3779.2729.33N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest EVTCY, TGTX, CYTK, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83CYTKCytokineticsN/A6.766.76EVTCYEvotec0.532.572.50TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CYTKCytokineticsN/AEVTCYEvotecN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%CYTKCytokinetics2.70%EVTCYEvotecN/ATGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million120.97 millionOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableEVTCY, TGTX, CYTK, and ACAD HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Takes $30.55 Million Position in TG Therapeutics, Inc. $TGTXSeptember 1 at 5:36 AM | marketbeat.comRafferty Asset Management LLC Has $7.17 Million Holdings in TG Therapeutics, Inc. $TGTXAugust 30 at 5:29 AM | marketbeat.comJump Financial LLC Buys New Shares in TG Therapeutics, Inc. $TGTXAugust 30 at 5:00 AM | marketbeat.comTG Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 28, 2025 | globenewswire.comRaymond James Financial Inc. Purchases 205,111 Shares of TG Therapeutics, Inc. $TGTXAugust 27, 2025 | marketbeat.comWellington Management Group LLP Boosts Position in TG Therapeutics, Inc. $TGTXAugust 26, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Position Decreased by 1832 Asset Management L.P.August 25, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLCAugust 23, 2025 | marketbeat.comTG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd.August 23, 2025 | marketbeat.comTG Therapeutics: Looking For The Stimulus For A TurnaroundAugust 20, 2025 | seekingalpha.comFox Run Management L.L.C. Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)August 19, 2025 | marketbeat.com746,696 Shares in TG Therapeutics, Inc. $TGTX Bought by Nuveen LLCAugust 19, 2025 | marketbeat.comInvesco Ltd. Raises Position in TG Therapeutics, Inc. $TGTXAugust 19, 2025 | marketbeat.comWealthedge Investment Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)August 17, 2025 | marketbeat.comSector Gamma AS Acquires Shares of 55,000 TG Therapeutics, Inc. (NASDAQ:TGTX)August 17, 2025 | marketbeat.comTG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You ThinkAugust 16, 2025 | finance.yahoo.comAigen Investment Management LP Purchases Shares of 9,522 TG Therapeutics, Inc. (NASDAQ:TGTX)August 14, 2025 | marketbeat.comPersistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)August 13, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment BoardAugust 13, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LPAugust 13, 2025 | marketbeat.comPandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)August 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVTCY, TGTX, CYTK, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$25.99 -0.24 (-0.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$25.83 -0.16 (-0.62%) As of 08/29/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Cytokinetics NASDAQ:CYTK$35.33 -2.02 (-5.41%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$35.78 +0.45 (+1.26%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Evotec OTCMKTS:EVTCY$3.50 -0.01 (-0.28%) As of 08/29/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.TG Therapeutics NASDAQ:TGTX$29.33 +0.37 (+1.28%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$29.37 +0.04 (+0.14%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
